Navigation Links
Control Your siRNA Research

Proven siRNA Controls and Matched Primary Antibodies

Gene Specific siRNA Controls
Whether you are starting out in siRNA research or you are an siRNA expert, you'll appreciate the convenience of the Silencer gene specific siRNA controls. Each Silencer gene specific siRNA control contains 50 g of ready-to-use chemically synthesized and gel purified GAPDH, cyclophilin, c-myc, or -actin siRNA, which is sufficient for 165 transfections (24 well plates). Also included are 25 g of a scrambled Negative Control siRNA and a detailed Instruction Manual. Each control is validated for use in human cell lines and each lot is functionally tested in an siRNA experiment. The GAPDH and cyclophilin siRNAs are also validated for use in mouse cell lines. These siRNA controls are ideal for developing and optimizing siRNA experiments.

Monitoring Transfection Efficiency
Because low transfection efficiency is the most frequent cause of unsuccessful gene silencing experiments, optimizing transfection conditions is critical. The Silencer Gene Specific siRNA Controls are ideal for this application, particularly when they are fluorescently labeled using the simple procedure provided with the Silencer siRNA Labeling Kits. Once transfected into cells, uptake of the labeled siRNA can be correlated to gene silencing by fluorescence microscopy using one of Ambion's new primary antibodies matched to our gene specific siRNA controls (Figure 1).

Figure 1. Characteristi cs of Ambion's Primary Antibodies for siRNA Research.

Primary Antibodies Matched to Silencer Gene Specific Controls
Ambion provides mouse monoclonal antibodies for the detection of GAPDH, c-myc, and -actin by immunofluorescence. Each of these primary antibodies has been used in immunofluorescence experiments at Ambion to detect the reduction in protein levels induced by siRNA. An example of such an experiment is shown in Figure 2. (Antibodies are supplied in solution in a 100 g unit size and are validated for use in immunofluorescence experiments. Note that the concentration and volume will vary by antibody).

Figure 2. Following the Silencing of -actin. An siRNA targeting -actin was labeled with Cy3 using the Silencer siRNA Labeling Kit. The labeled siRNA was transfected into HeLa cells and cells were analyzed 96 hours later. Green: -actin protein detected with anti--actin (Ambion) and a fluorescein labeled secondary antibody. Red: Cy3 labeled siRNA. Blue: DAPI stained nuclei. (Cy3 is a trademark of Amersham Biosciences.)

back to top

Ordering Information
Cat# Product Name Size 1632 Silencer siRNA Labeling Kit - Cy3 65 g labeled siRNA 1634 Silencer siRNA Labeling Kit - FAM 65 g labeled siRNA 4300 anti-GAPDH, mouse monoclonal 6C5 100 g 4302 anti-beta-actin, mouse monoclonal AC-15 100 g


Page: All 1 2 3

Related biology technology :

1. Control RT-PCR Primers for Human Gene Transcripts with Varying Abundance
2. Versatile Vectors for Ponasterone A- Inducible Control of Gene Expression in Mammalian Cells
3. Human t-PA Control Primer Set
4. Rapid PCR* Using Active Tube Temperature Control On Thermos PCR Machines
5. Housekeeping Genes: Universal Positive Controls in siRNA Knockdown Experiments
6. Designing Controls for siRNA Experiments
7. RNAi: The Controls You Need
8. RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control
9. Long-Term Instrument Control and Connectivity Solutions
10. Rapamycin Optimized in 100 Liter Fermentor Using BioCommand Control Strategys
11. Custom and library siRNA for efficient gene silencing
Post Your Comments:

(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
Breaking Biology News(10 mins):